JPRN-UMIN000040619招募中未知
Pemafibrate for prevention of atherosclerotic diseases in patients with stroke or transient ischemic attack - Pemafibrate for prevention of atherosclerotic diseases in stroke patients (PPAR-Stroke)
Tokyo Women's Medical University0 个研究点目标入组 200 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Contraindications for pemafibrate (e.g., allergy to the drug, severe kidney dysfunction, pregnancy etc.) 2. Patients who have a history of or plan to undergo carotid endarterectomy/carotid stenting 3. Patients who had received pemafibrate before index event
研究者
相似试验
进行中（未招募）
1 期
Pemafibrate to reduce risk of cardiovascular events in patients with diabetes.EUCTR2016-003818-26-HUKowa Research Institute, Inc.10,000
进行中（未招募）
1 期
Pemafibrate to reduce risk of cardiovascular events in patients with diabetes.Reduction of cardiovascular events in patients with Type II DiabetesMedDRA version: 20.0Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 100000004860EUCTR2016-003818-26-DEKowa Research Institute, Inc.10,000
进行中（未招募）
1 期
Pemafibrate to reduce risk of cardiovascular events in patients with diabetes.EUCTR2016-003818-26-SKKowa Research Institute, Inc.10,000
进行中（未招募）
1 期
Pemafibrate to reduce risk of cardiovascular events in patients with diabetes.Reduction of cardiovascular events in patients with Type II DiabetesMedDRA version: 20.0Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 100000004860EUCTR2016-003818-26-DKKowa Research Institute, Inc.10,000
进行中（未招募）
1 期
Pemafibrate to reduce risk of cardiovascular events in patients with diabetes.Reduction of cardiovascular events in patients with Type II DiabetesMedDRA version: 20.0Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 100000004860EUCTR2016-003818-26-BGKowa Research Institute, Inc.